myBRCA HiRisk

myBRCA HiRisk is a screening test that identifies mutations in 26 genes, including BRCA1 and BRCA2, which are associated with increased risk for developing breast, ovarian, and other inherited cancers.

Contact us to schedule an appointment

You might consider myBRCA HiRisk if you or one of your close relatives* has one or more of the following:

  • Breast cancer at or before age 50
  • 2 or more primary breast cancers in the same individual
  • Ovarian cancer, fallopian tube cancer or primary peritoneal cancer
  • Breast AND ovarian cancer in the same individual
  • Male breast cancer
  • Identification of hereditary breast and ovarian cancer causing genetic mutations in a close blood relative
  • 3 or more of the following cancers: Breast, ovarian, fallopian tube, primary peritoneal, endometrial, pancreatic, prostate, thyroid, colorectal, sarcoma, adrenocortical carcinoma, brain, gastric, gastrointestinal polyps, leukemia, melanoma, and/or kidney

*Close blood relatives: first-degree (parents, children, siblings), second-degree (grandparents, aunts/uncles, nieces/nephews, half siblings), and third degree (first cousins, great aunts/ uncles/grandparents)

If you are not at high risk but still interested in a screening test, please check out myBRCA

Test Details

The myBRCA HiRisk test screens these 26 genes:

ATM BARD1 BLM BRCA1 BRCA2 BRIP1 CDH1 CHEK2 EPCAM FAM175A MEN1 MLH1 MRE11A
MSH2 MSH6 MUTYH NBN PALB2 PMS2 PTEN RAD50 RAD51C RAD51D STK11 TP53 XRCC2
More Information on the 26 Genes

These genes account for over 98% of known genetic causes of hereditary breast and ovarian cancer, and may also be associated with increased risk for:

Cancer Types

  • Colorectal cancer
  • Endometrial cancer
  • Melanoma
  • Pancreatic cancer
  • Gastric cancer
  • Others

Hereditary Cancer Syndromes

  • Cowden syndrome
  • Li-Fraumeni syndrome
  • Peutz-Jeghers syndrome
  • Lynch syndrome

The BRCA genes are part of your body’s natural defense system. They help protect you from developing certain cancers.

If you have a BRCA gene that is not working properly (meaning, it carries a harmful), your lifetime risk to develop breast, ovarian and other cancers increases significantly.1

Lifetime Breast Cancer Risk

The average lifetime risk of breast cancer in Central and South America (by age 80) is up to 10%. A BRCA mutation can increase your risk up to 80%. 3

Lifetime Ovarian Cancer Risk

The average lifetime risk of ovarian cancer in Central and South America (by age 80) is up to 1%. A BRCA mutation can increase your risk up to 40%. 3

See references below

Why should you get screened?

The myBRCA HiRisk test will:

  • Help you understand your risk for developing hereditary breast, ovarian, and other inherited cancers
  • Help identify family members who are potentially at risk
  • Improve the odds of early detection and prevention
  • Help guide Help guide management and/or treatment options depending on which genes are involved

How it works

  1. Contact South Genetics to make an appointment
  2. Attend your appointment where your blood sample will be collected
  3. Your blood sample will be processed in VeritasGenetics’ CLIA approved laboratory
  4. The results will be delivered to you and your doctor

Technical Information

  • Targeted next generation sequencing assay for 26 hereditary cancer genes.
  • BRCA1 and BRCA2 large rearrangement analysis included (>99.9% sensitivity and specificity).
  • Point mutations and small insertions/deletions are detected (>99.9% sensitivity and specificity).
  • Likely pathogenic or pathogenic intronic variants up to 10 base pairs from the coding region are always reported.
  • Variant classification based on ACMG Guidelines.

Download for more information:

Technical Information Validation White Paper

About VeritasGenetics

VeritasGenetics is a global pioneer in disease prevention through accessible genetic information. By removing the barriers to genetic screening, Veritas empowers individuals and doctors to make informed lifestyle decisions that can lead to disease prevention and longer and healthier lives. Veritas is founded by leaders in genomics from Harvard Medical School and operates globally from its o ces in the U.S., Europe and China.

Contact

+58 (212) 961-9611 / 9539 / 9456 / 9548 / 9451 +58 (0424) 254-3868 / +58 (0412) 273-8815 /

Centro Comercial Paseo El Hatillo, Torre de Oficinas, Piso 9, Ofic. 9-04 Urbanización La Lagunita / Caracas – Venezuela

infovenezuela@southgenetics.com

References

  • Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 378(9801):1461-84, 2011.
  • Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 20/July/2016.
  • 1-National Cancer Institute. BRCA1 & BRCA2: Cancer Risk & Genetic Testing. 2015.NCI
  • 2-National Cancer Institute. BRCA1 & BRCA2: American Cancer Society. Breast cancer risk factors you cannot change. 2015.ACS
  • 3-Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2013 Sep 26]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from:NCBI